Provention Bio (PRVB) Wisely Yanks Offering
Management at Provention Bio (PRVB) jumped the gun on the capital raise. But thankfully they ranked it to avoid unnecessary dilution. Here’s why DTR believes it was a bullish move…
Management at Provention Bio (PRVB) jumped the gun on the capital raise. But thankfully they ranked it to avoid unnecessary dilution. Here’s why DTR believes it was a bullish move…
Management at Provention Bio (PRVB) jumped the gun on the capital raise after the positive readout for “At-Risk” patients for Type 1 Diabetes, but here’s why it will work out ok…
Five key takeaways from Cue Biopharma’s Q1 2019 report, including the list of catalysts management believes will result in 2019 being a “transformational” year…
Here are three reasons why today’s FDA approval to enter the clinic with CUE-101 for HPV-associated cancers is significant, including two not so obvious reasons. Plus, a list of catalysts for 2019…
Here are the four keys to watch for when up-and-coming biotech Cue Biopharma (CUE) reports results today